Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

Blood (2024) 144 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2024-210134

Published: 2024

Journal Articles

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Shai O. Shimony, Heardley Murdock, Julia Keating, Christopher R. Reilly, Harrison K. Tsai, Christopher J. Gibson, Stefan Faderl, Tony Wagner, Nalina Dronamraju, Tara L. Lin, Ellen K. Ritchie, Thomas Prebet, Jorge E. Cortes, Geoffrey L. Uy, Jeffrey E Lancet, Donna S. Neuberg, Richard M. Stone, R. Coleman Lindsley

Blood (2024) 144 (Supplement 1): 60.

https://doi.org/10.1182/blood-2024-200413

Published: 2024

Journal Articles

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Justin Grenet, Neela Easwar, Akriti G. Jain, Madelyn Burkart, Xiaoyue Ma, Paul Christos, Ellen K. Ritchie, Michael Samuel, Justin D. Kaner, Jonathan Canaani, Aaron D. Goldberg, Shira N. Dinner, Kendra L. Sweet, Gail J. Roboz, Pinkal Desai

Blood (2024) 144 (Supplement 1): 2867.

https://doi.org/10.1182/blood-2024-206340

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Journal Articles

Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study

Abdulraheem Yacoub, Ellen K. Ritchie, Naveen Pemmaraju, Richard Zuniga, Erin L. Crowgey, Cynthia Timmers, Patricia Feldman, J.E. Hamer-Maansson, Tricia Kalafut, Evan M. Braunstein, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2024-199810

Published: 2024

Journal Articles

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Blood (2024) 144 (Supplement 1): 970.

https://doi.org/10.1182/blood-2024-202365

Published: 2024

Journal Articles

Opening Pandora's Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia

Gail J. Roboz, Nuria Mencia-Trinchant, Gabriela Pereira, Ellen K. Ritchie, Justin D. Kaner, Michael Samuel, Michal Bar-Natan, Jonathan Canaani, Sharmaine Griffith-Baker, Pinkal Desai, Monica L Guzman

Blood (2024) 144 (Supplement 1): 1576.

https://doi.org/10.1182/blood-2024-212090

Published: 2024

Journal Articles

Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Aaron T. Gerds, Andrew T. Kuykendall, Marina Kremyanskaya, Ellen K. Ritchie, Jason Gotlib, Jeanne Palmer, Kristen M. Pettit, Victor Priego, Uttam Kumar Nath, Abdulraheem Yacoub, Arkapal Bandyopadhyay, Suneel Gupta, Sarita Khanna, Arturo Molina, Naveen Pemmaraju

Blood (2024) 144 (Supplement 1): 4559.

https://doi.org/10.1182/blood-2024-197985

Published: 2024

Journal Articles

Acute Leukemias of Ambiguous Lineage Have Durable Response to Hypomethylating Agents Plus Venetoclax in Older Patients

Joshua A Fein, Sanjay Patel, Neela Easwar, Michal Bar-Natan, Amy Chadburn, Pinkal Desai, Julia Geyer, Michael Kluk, Madhu M Ouseph, Ellen K. Ritchie, Michael Samuel, Paul Simonson, Gail J. Roboz, Justin D. Kaner

Blood (2023) 142 (Supplement 1): 1531.

https://doi.org/10.1182/blood-2023-190532

Published: 2023

Journal Articles

Molecular and Cytogenetic Characteristics of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Patients Exposed to Chemotherapy (CT) and/or Radiation (XRT)

Pinkal Desai, Yasmin Abaza, Hetty E. Carraway, Jason Chua, Michael Samuel, Cynthia Crispino, Bridget Foley, Sindhusha Veeraballi, Peter Doukas, Oluwatobi Odetola, Justin D. Kaner, Michal Bar-Natan, Ellen K. Ritchie, Gail J. Roboz

Blood (2023) 142 (Supplement 1): 821.

https://doi.org/10.1182/blood-2023-190478

Published: 2023

Journal Articles

Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study

Ellen K. Ritchie, Kristen Marie Pettit, Andrew T. Kuykendall, Marina Kremyanskaya, Naveen Pemmaraju, Sarita Khanna, Arturo Molina, Suneel Gupta

Blood (2023) 142 (Supplement 1): 745.

https://doi.org/10.1182/blood-2023-178253

Published: 2023

Journal Articles

Clinical and Disease Characteristics of Patients with Myelofibrosis and Essential Thrombocythemia Who Harbor a Calreticulin (CALR) Gene Mutation: Subanalysis of the MOST Study

Stephen T. Oh, Naveen Pemmaraju, Niyati Nathwani, Evan M. Braunstein, JE Hamer-Maansson, Tricia Kalafut, Ellen K. Ritchie

Blood (2023) 142 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2023-179507

Published: 2023

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)

Joseph M. Scandura, Aaron T. Gerds, Ellen K. Ritchie, Xulong Wang, Steve Kye, Raajit K. Rampal

Blood (2023) 142 (Supplement 1): 3211.

https://doi.org/10.1182/blood-2023-181720

Published: 2023

Journal Articles

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Blood (2023) 142 (Supplement 1): 624.

https://doi.org/10.1182/blood-2023-179291

Published: 2023

Journal Articles

Impact of Graft Source [Cord Blood Supported By CD34+ Selected Cells (Haplo-Cord) Vs. Matched Donor] on Transplant Outcomes in Myelofibrosis

Nima Ghalehsari, Zhengming Chen, Sebastian A. Mayer, Ghaith Abu-Zeinah, Tsiporah B. Shore, Ellen K. Ritchie, Richard T. Silver, Andrew I. Schafer, Joseph M. Scandura, Gail J. Roboz, Koen Van Besien, Alexandra Gomez-Arteaga

Blood (2023) 142 (Supplement 1): 6953.

https://doi.org/10.1182/blood-2023-185075

Published: 2023

Journal Articles

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Blood (2023) 142 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2023-180945

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Spencer Krichevsky, BS, Ghaith Abu Zeinah, MD, Claudia Sosner, BA, Diana Jaber, BA, Niamh Savage, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Richard T. Silver, MD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 1664.

https://doi.org/10.1182/blood-2019-131605

Published: 2019

Journal Articles

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Pinkal Desai, MDMPH, Niamh Savage, BA, Spencer Krichevsky, BS, Tania Curcio, Sangmin Lee, MD, Michael B. Samuel, MD, Ellen K. Ritchie, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1666.

https://doi.org/10.1182/blood-2019-127663

Published: 2019

NARROW

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Opening Pandora's Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia

Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Acute Leukemias of Ambiguous Lineage Have Durable Response to Hypomethylating Agents Plus Venetoclax in Older Patients

Molecular and Cytogenetic Characteristics of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Patients Exposed to Chemotherapy (CT) and/or Radiation (XRT)

Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study

Clinical and Disease Characteristics of Patients with Myelofibrosis and Essential Thrombocythemia Who Harbor a Calreticulin (CALR) Gene Mutation: Subanalysis of the MOST Study

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Impact of Graft Source [Cord Blood Supported By CD34+ Selected Cells (Haplo-Cord) Vs. Matched Donor] on Transplant Outcomes in Myelofibrosis

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only